برجاء الإنتظار ...

Search Results



نشرة الممارس الصحي نشرة معلومات المريض بالعربية نشرة معلومات المريض بالانجليزية صور الدواء بيانات الدواء
  SFDA PIL (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)

Ambiful contains the active substance fulvestrant, which belongs to the group of estrogen blockers. Estrogens, a type of female sex hormones, can in some cases be involved in the growth of breast cancer.

Ambiful is used either:

–  alone, to treat postmenopausal women with a type of breast cancer called estrogen receptor positive

breast cancer that is locally advanced or has spread to other parts of the body (metastatic), or

–  in combination with palbociclib to treat women with a type of breast cancer called hormone receptor- positive, human epidermal growth factor receptor 2-negative breast cancer, that is locally advanced or has spread to other parts of the body (metastatic). Women who have not reached menopause will also be treated with a medicine called a luteinizing hormone releasing hormone (LHRH) agonist.

When Ambiful is given in combination with palbociclib, it is important that you also read the package leaflet for palbociclib. If you have any questions about palbociclib, please ask your doctor.


  1. Do not use Ambiful:

    – if you are allergic to fulvestrant or to any of the other ingredients of this medicine (listed in section 6) – if you are pregnant or breast-feeding
    – if you have severe liver problems

    Warnings and precautions

    Talk to your doctor, pharmacist or nurse before using Ambiful if any of these apply to you: – kidney or liver problems
    – low numbers of platelets (which help blood clotting) or bleeding disorders
    – previous problems with blood clots

    – osteoporosis (loss of bone density) – alcoholism

    Children and adolescents

    Ambiful is not indicated in children and adolescents under 18 years.

    Other medicines and Ambiful

    Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, you should tell your doctor if you are using anticoagulants (medicines to prevent blood clots).

    Pregnancy and breast-feeding

    You must not use Ambiful if you are pregnant. If you can become pregnant, you should use effective contraception while being treated with Ambiful.

    You must not breast-feed while on treatment with Ambiful.

    Driving and using machines

    Ambiful is not expected to affect your ability to drive or use machines. However, if you feel tired after treatment do not drive or use machines.

    Ambiful contains ethanol

    Ambiful contains 10 vol % ethanol (alcohol), i.e. up to 500 mg per syringe, equivalent to 10 ml beer or 4 ml wine per syringe.
    Harmful for those suffering from alcoholism.
    To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy.

    Ambiful contains benzyl alcohol

    Ambiful contains 500 mg benzyl alcohol in each syringe which is equivalent to 100 mg/ml.
    Benzyl alcohol may cause allergic reactions. Increased risk in young children.
    Ask your doctor or pharmacist for advice if you are pregnant or breast-feeding or if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called “metabolic acidosis”).

    Ambiful contains benzyl benzoate

    Ambiful contains 750 mg benzyl benzoate in each syringe which is equivalent to 150 mg/ml.


Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is 500 mg fulvestrant (two 250 mg/5 ml injections) given once a month with an additional 500 mg dose given 2 weeks after the initial dose.

Your doctor will give you Ambiful as a slow intramuscular injection, one into each of your buttocks. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.


  1. Like all medicines, this medicine can cause side effects, although not everybody gets them.

    You may need immediate medical treatment if you experience any of the following side effects:

    • Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/or throat that may be signs of anaphylactic reactions

    • Thromboembolism (increased risk of blood clots)*

    • Inflammation of the liver (hepatitis)

    • Liver failure

      Tell your doctor, pharmacist or nurse if you notice any of the following side effects:

      Very common side effects (may affect more than 1 in 10 people) • Injection site reactions, such as pain and/or inflammation
      • Abnormal levels of liver enzymes (in blood tests) *
      • Nausea (feeling sick)

      • Weakness, tiredness*


Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or syringe labels after EXP. The expiry date refers to the last day of that month.

Store below 25 °C. Store the pre-filled syringe in the original package in order to protect from light.

Your healthcare professional will be responsible for the correct storage, use and disposal of Ambiful.

This medicine may pose a risk to the aquatic environment.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


–  The active substance is fulvestrant. Each pre-filled syringe (5 ml) contains 250 mg fulvestrant. Each ml contains 50 mg fulvestrant.

–  The other ingredients (excipients) are ethanol (96%), benzyl alcohol, benzyl benzoate, virgin castor oil. – Each pre-filled syringe contains 10 vol % ethanol (alcohol), i.e. up to 500 mg ethanol.
– Each pre-filled syringe contains 500 mg benzyl alcohol which is equivalent to 100 mg/ml.
– Each pre-filled syringe contains 750 mg benzyl benzoate which is equivalent to 150 mg/ml.


Ambiful is a clear, colourless to yellow, viscous solution, practically free from particles, in a pre-filled type I glass syringe fitted with bromobutyl rubber stopper, plunger rod and backstop, fitted with a tamper- evident closure, containing 5 ml solution for injection. Two syringes must be administered to receive the 500 mg recommended monthly dose. Ambiful has 2 pack presentations, either a pack containing 1 glass pre-filled syringe or a pack containing 2 glass pre-filled syringes. 21G x 11⁄2 inch safety needles (BD SafetyGlideTM) for connection to each barrel are also provided. Bundle packs: 2 x 2 pre-filled syringes (5 ml each) 3 x 2 pre-filled syringes (5 ml each) Not all pack sizes may be marketed.

Marketing Authorisation Holder

EVER Valinject GmbH Oberburgau 3
4866 Unterach am Attersee Austria

Manufacturer

EVER Pharma Jena GmbH Otto-Schott-Strasse 15 07745 Jena
Germany


JULY/2020
  نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)

ﯾﺤﺘﻮي أﻣﺒﯿﻔﻮل ﻋﻠﻰ اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ﻓﻮﻟﻔﺴﺘﺮاﻧﺖ اﻟﺘﻲ ﺗﻨﺘﻤﻲ إﻟﻰ ﻣﺠﻤﻮﻋﺔ ﺣﺎﺻﺮات ھﺮﻣﻮن اﻻﺳﺘﺮوﺟﯿﻦ .ﯾﻤﻜﻦ أن ﯾﻜﻮنھﺮﻣﻮن اﻻﺳﺘﺮوﺟﯿﻦ، وھﻮ ﻧﻮع ﻣﻦ اﻟﮭﺮﻣﻮﻧﺎت اﻟﺠﻨﺴﯿﺔ اﻷﻧﺜﻮﯾﺔ، ﺳﺒﺐ

ﻓﻲ ﺑﻌﺾ ﺣﺎﻻت ﻓﻲ ﻧﻤﻮ ﺳﺮطﺎن اﻟﺜﺪي.

ﯾﺘﻢ اﺳﺘﺨﺪام أﻣﺒﯿﻔﻮل إﻣﺎ:

-   وﺣﺪه، ﻟﻌﻼج اﻟﻨﺴﺎء ﻓﻲ ﺣﺎﻻت ﻣﺎ ﺑﻌﺪ اﻧﻘﻄﺎع اﻟﻄﻤﺚ واﻟﻤﺼﺎﺑﺎت ﺑﻨﻮع ﻣﻦ ﺳﺮطﺎن اﻟﺜﺪي ﯾﺴﻤﻰ

ﺳﺮطﺎن اﻟﺜﺪي اﻹﯾﺠﺎﺑﻲ ﻟﻤﺴﺘﻘﺒﻼت ھﺮﻣﻮن اﻻﺳﺘﺮوﺟﯿﻦ واﻟﺬي ﯾﻜﻮن ﻣﺘﻘﺪ ًﻣﺎ ﺑﺸﻜﻞ ﻣﺤﻠﻲ أو

ﻣﻨﺘﺸ ًﺮا ﻓﻲ أﺟﺰاء أﺧﺮى ﻣﻦ اﻟﺠﺴﻢ )ﻧﻘﯿﻠﻲ(، أو

-   ﺑﺎﻟﺘﺰاﻣﻦ ﻣﻊ ﺑﺎﻟﺒﻮﺳﯿﻜﻠﯿﺐ ﻟﻌﻼج اﻟﻨﺴﺎء اﻟﻤﺼﺎﺑﺎت ﺑﻨﻮع ﻣﻦ ﺳﺮطﺎن اﻟﺜﺪي ﯾﺴﻤﻰ ﻣﺴﺘﻘﺒﻼت

اﻟﮭﺮﻣﻮﻧﺎت اﻹﯾﺠﺎﺑﯿﺔ، ﻣﺴﺘﻘﺒﻼت ﻋﺎﻣﻞ ﻧﻤﻮ اﻟﺠﻠﺪ اﻟﺒﺸﺮي

-   ﺳﺮطﺎن اﻟﺜﺪي اﻟﺴﻠﺒﻲ، اﻟﺬي ﯾﻜﻮن ﻣﺘﻘﺪ ًﻣﺎ ﺑﺸﻜﻞ ﻣﺤﻠﻲ أو ﻣﻨﺘﺸﺮ ﻓﻲ أﺟﺰاء أﺧﺮى ﻣﻦ اﻟﺠﺴﻢ

ﻻ ﺗﺴﺘﺨﺪم أﻣﺒﯿﻔﻮل

– إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ اﻟﺤﺴﺎﺳﯿﺔ ﺗﺠﺎه ﻓﻮﻟﻔﺴﺘﺮاﻧﺖ أو ﻷي ﻣﻦ اﻟﻤﻜﻮﻧﺎت اﻷﺧﺮى ﻟﮭﺬا اﻟﺪواء اﻟﻤﺬﻛﻮرة

ﻓﻲ اﻟﻘﺴﻢ .(6)

إذا ﻛﻨﺖ ﺣﺎﻣﻼً أو ﻣﺮﺿﻌﺔ

–إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ ﻣﺸﺎﻛﻞ ﺣﺎدة ﻓﻲ اﻟﻜﺒﺪ

اﻟﺘﺤﺬﯾﺮات واﻻﺣﺘﯿﺎطﺎت

ﺗﺤﺪث إﻟﻰ طﺒﯿﺒﻚ، اﻟﺼﯿﺪﻟﻲ أو اﻟﻤﻤﺮض ﻗﺒﻞ اﺳﺘﺨﺪام أﻣﺒﯿﻔﻮل إذا ﻛﺎن أي ﻣﻤﺎ ﯾﻠﻲ ﯾﺴﺮي ﻋﻠﯿﻚ:

- ﻣﺸﺎﻛﻞ ﻓﻲ اﻟﻜﻠﻰ أو اﻟﻜﺒﺪ

- اﻧﺨﻔﺎض أﻋﺪاد اﻟﺼﻔﺎﺋﺢ اﻟﺪﻣﻮﯾﺔ اﻟﺘﻲ ﺗﺴﺎﻋﺪ ﻋﻠﻰﺗﺨﺜﺮ اﻟﺪم )أو اﺿﻄﺮاﺑﺎت اﻟﻨﺰﯾﻒ

- ﻣﺸﺎﻛﻞ ﺳﺎﺑﻘﺔ ﻣﻊ ﺟﻠﻄﺎت اﻟﺪم

- ھﺸﺎﺷﺔ اﻟﻌﻈﺎم )ﻓﻘﺪان ﻛﺜﺎﻓﺔ اﻟﻌﻈﺎم(

- إدﻣﺎن اﻟﻜﺤﻮل

اﻷطﻔﺎل واﻟﻤﺮاھﻘﻮن

ﯾﻮﺻﻰ ﺑﻌﺪم إﻋﻄﺎء أﻣﺒﯿﻔﻮل ﻓﻲ ﺣﺎﻟﺔ اﻷطﻔﺎل واﻟﻤﺮاھﻘﯿﻦ أﻗﻞ ﻣﻦ 18 عام

اﻷدوﯾﺔ اﻷﺧﺮى وأﻣﺒﯿﻔﻮل

أﺧﺒﺮ طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ إذا ﻛﻨﺖ ﺗﺘﻨﺎول، أو ﺗﻨﺎوﻟﺖ ﻣﺆﺧ ًﺮا، أو ﻗﺪ ﺗﺘﻨﺎول أي أدوﯾﺔ أﺧﺮى

وﻋﻠﻰ وﺟﮫ اﻟﺨﺼﻮص، ﯾﺠﺐ ﻋﻠﯿﻚ إﺧﺒﺎر طﺒﯿﺒﻚ إذا ﻛﻨﺖ ﺗﺴﺘﺨﺪم ﻣﻀﺎدات اﻟﺘﺨﺜﺮ (أدوية لمنع جلطات الدم) 

اﻟﺤﻤﻞ واﻹرﺿﺎع

ﯾﺠﺐ أﻻ ﺗﺴﺘﺨﺪم أﻣﺒﯿﻔﻮل إذا ﻛﻨﺖ ﺣﺎﻣﻼً .إذا ﻛﻨﺖ ﻗﺪ ﺗﺼﺒﺤﯿﻦ ﺣﺎﻣﻞ، ﻓﯿﺠﺐ ﻋﻠﯿﻚ اﺳﺘﺨﺪام وﺳﺎﺋﻞ ﻣﻨﻊ

اﻟﺤﻤﻞ اﻟﻔﻌﺎﻟﺔ أﺛﻨﺎء اﻟﻌﻼج ﺑـ أﻣﺒﯿﻔﻮل.

ﯾﺠﺐ ﻋﻠﯿﻚ ﻋﺪم ﻣﻤﺎرﺳﺔ اﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ أﺛﻨﺎء اﻟﻌﻼج ﺑـ أﻣﺒﯿﻔﻮل.

اﻟﻘﯿﺎدة واﺳﺘﺨﺪام اﻵﻻت

ﻣﻦ ﻏﯿﺮ اﻟﻤﺘﻮﻗﻊ أن ﯾﺆﺛﺮ دواء أﻣﺒﯿﻔﻮل ﻋﻠﻰ ﻗﺪرﺗﻚ ﻋﻠﻰ اﻟﻘﯿﺎدة أو اﺳﺘﺨﺪام اﻵﻻت

ﺷﻌﺮت ﺑﺎﻟﺘﻌﺐ ﺑﻌﺪ اﻟﻌﻼج، ﻓﻼ ﺗﻘﻢ ﺑﺎﻟﻘﯿﺎدة أو اﺳﺘﺨﺪام اﻵﻻت.

ﯾﺤﺘﻮي أﻣﺒﯿﻔﻮل ﻋﻠﻰ اﻹﯾﺜﺎﻧﻮل

ﯾﺤﺘﻮي أﻣﺒﯿﻔﻮل ﻋﻠﻰ 10% ﻣﻦ اﻹﯾﺜﺎﻧﻮل اﻟﻜﺤﻮل، أي ﻣﺎ ﯾﺼﻞ إﻟﻰ 500 ﻣﻠﻎ ﻟﻜﻞ ﺣﻘﻨﺔ، أي ﻣﺎ ﯾﻌﺎدل 10 ﻣﻞ ﻣﻦ اﻟﺒﯿﺮة أو 4 ﻣﻞ ﻣﻦ اﻟﻨﺒﯿﺬ ﻟﻜﻞ ﺣﻘﻨﺔ.

 

ﻣﻀﺮ ﻟﻤﻦ ﯾﻌﺎﻧﻮن ﻣﻦ إدﻣﺎن اﻟﻜﺤﻮل.

ﯾﺠﺐ أن ﯾﺆﺧﺬ ﺑﻌﯿﻦ اﻻﻋﺘﺒﺎر اﻟﻨﺴﺎء اﻟﺤﻮاﻣﻞ أو اﻟﻤﺮﺿﻌﺎت، واﻷطﻔﺎل، واﻟﻔﺌﺎت اﻟﻤﻌﺮﺿﺔ ﻟﻠﺨﻄﺮ ﻣﺜﻞ

اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﻌﺎﻧﻮن ﻣﻦ أﻣﺮاض اﻟﻜﺒﺪ، أو اﻟﺼﺮع.

ﯾﺤﺘﻮي أﻣﺒﯿﻔﻮل ﻋﻠﻰ ﻛﺤﻮل اﻟﺒﻨﺰﯾﻞ

ﯾﺤﺘﻮي أﻣﺒﯿﻔﻮل ﻋﻠﻰ 500 ﻣﻠﻎ ﻣﻦ ﻛﺤﻮل اﻟﺒﻨﺰﯾﻞ ﻓﻲ ﻛﻞ ﺣﻘﻨﺔ وھﻮ ﻣﺎ ﯾﻌﺎدل 100ﻣﻠﻎ/ﻣﻞ. ﻗﺪ ﯾﺴﺒﺐ ﻛﺤﻮل اﻟﺒﻨﺰﯾﻞ ﺗﻔﺎﻋﻼت ﺣﺴﺎﺳﯿﺔ .زﯾﺎدة اﻟﻤﺨﺎطﺮ ﻋﻨﺪ اﻷطﻔﺎل اﻟﺼﻐﺎر. 

اﺳﺄل طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ ﻟﻠﺤﺼﻮل ﻋﻠﻰ اﻟﻤﺸﻮرة إذا ﻛﻨﺖ ﺣﺎﻣﻼً أو ﻣﺮﺿﻌﺔ أو إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦﻣﺮض ﻓﻲ اﻟﻜﺒﺪ أو اﻟﻜﻠﻰ .وذﻟﻚ ﻷن ﻛﻤﯿﺎت ﻛﺒﯿﺮة ﻣﻦ ﻛﺤﻮل اﻟﺒﻨﺰﯾﻞ ﯾﻤﻜﻦ أن ﺗﺘﺮاﻛﻢ ﻓﻲ ﺟﺴﻤﻚ وﻗﺪﺗﺴﺒﺐ آﺛﺎ ًرا ﺟﺎﻧﺒﯿﺔ )ﺗﺴﻤﻰ "اﻟﺤﻤﺎض اﻷﯾﻀﻲ.

ﯾﺤﺘﻮي أﻣﺒﯿﻔﻮل ﻋﻠﻰ ﺑﻨﺰوات اﻟﺒﻨﺰﯾﻞ

ﯾﺤﺘﻮي أﻣﺒﯿﻔﻮل ﻋﻠﻰ 750ﻣﻠﻎ ﻣﻦ ﺑﻨﺰوات اﻟﺒﻨﺰﯾﻞ ﻓﻲ ﻛﻞ ﺣﻘﻨﺔ أي ﻣﺎ ﯾﻌﺎدل 150 ﻣﻠﻎ/مل

https://localhost:44358/Dashboard

اﺳﺘﺨﺪم ھﺬا اﻟﺪواء ﺑﺎﻟﻀﺒﻂ ﻛﻤﺎ أﺧﺒﺮك طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ اﺳﺘﺸﺮ طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ إذا ﻟﻢ ﺗﻜﻦ ﻣﺘﺄﻛﺪًا.

اﻟﺠﺮﻋﺔ اﻟﻤﻮﺻﻰ ﺑﮭﺎ ھﻲ 500ﻣﻠﻎ ﻣﻦ ﻣﺎدة ﻓﻮﻟﻔﯿﺴﺘﺮاﻧﺖ ﺣﻘﻨﺘﯿﻦ  250 ﻣﻠﻎ ٥/مل  ﺗﻌﻄﻰ ﻣﺮة واﺣﺪة ﻓﻲ اﻟﺸﮭﺮ ﻣﻊ ﺟﺮﻋﺔ إﺿﺎﻓﯿﺔ 500ﻣﻠﻎ ﺗﻌﻄﻰ ﺑﻌﺪ أﺳﺒﻮﻋﯿﻦ ﻣﻦ اﻟﺠﺮﻋﺔ اﻷوﻟﯿﺔ. 

ﺳﻮف ﯾﻌﻄﯿﻚ طﺒﯿﺒﻚ أﻣﺒﯿﻔﻮل ﻛﺤﻘﻨﺔ ﻋﻀﻠﯿﺔ ﺑﻄﯿﺌﺔ، واﺣﺪة ﻓﻲ ﻛﻞ ﻣﻦ اﻷرداف. ﻓﻲ ﺣﺎﻟﺔ وﺟﻮد أياﺳﺘﻔﺴﺎرات أﺧﺮى ﺣﻮل اﺳﺘﺨﺪام ھﺬا اﻟﺪواء، اﺳﺄل طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ أو

اﻟﻤﻤﺮﺿﺔ.

 

ﻣﺜﻞ ﺟﻤﯿﻊ اﻷدوﯾﺔ، ھﺬا اﻟﺪواء ﻗﺪ ﯾﺴﺒﺐ آﺛﺎر ﺟﺎﻧﺒﯿﺔ وﻟﻜﻨﮭﺎ ﻻ ﺗﺼﯿﺐ اﻟﺠﻤﯿﻊ.

 

ﻗﺪ ﺗﺤﺘﺎج إﻟﻰ ﻋﻼج طﺒﻲ ﻓﻮري إذا واﺟﮭﺖ أﯾًﺎ ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﺎﻟﯿﺔ:

ردود ﻓﻌﻞ اﻟﺤﺴﺎﺳﯿﺔ )ﻓﺮط اﻟﺤﺴﺎﺳﯿﺔ(، ﺑﻤﺎ ﻓﻲ ذﻟﻚ ﺗﻮرم اﻟﻮﺟﮫ واﻟﺸﻔﺘﯿﻦ واﻟﻠﺴﺎن و/أو اﻟﺤﻠﻖ

واﻟﺘﻲ ﻗﺪ ﺗﻜﻮن ﻋﻼﻣﺎت ﻋﻠﻰ ردود ﻓﻌﻞ اﻟﺤﺴﺎﺳﯿﺔ

•   اﻟﺠﻠﻄﺎت اﻟﺪﻣﻮﯾﺔ (زﯾﺎدة ﺧﻄﺮ ﺟﻠﻄﺎت اﻟﺪم*)

•   اﻟﺘﮭﺎب اﻟﻜﺒﺪ

•   اﻟﺘﻠﯿﻒ اﻟﻜﺒﺪى

أﺧﺒﺮ طﺒﯿﺒﻚ أو اﻟﺼﯿﺪﻟﻲ أو اﻟﻤﻤﺮﺿﺔ إذا ﻻﺣﻈﺖ أﯾًﺎ ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﺎﻟﯿﺔ:

اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺸﺎﺋﻌﺔ ﺟﺪاً )ﻗﺪ ﺗﺼﯿﺐ أﻛﺜﺮ ﻣﻦ 1 من كل 10 أشخاص

•   ﺗﻔﺎﻋﻼت ﻣﻮﻗﻊ اﻟﺤﻘﻦ، ﻣﺜﻞ اﻷﻟﻢ و/أو اﻻﻟﺘﮭﺎب

•   ﻣﺴﺘﻮﯾﺎت ﻏﯿﺮ طﺒﯿﻌﯿﺔ ﻣﻦ إﻧﺰﯾﻤﺎت اﻟﻜﺒﺪ )ﻓﻲ اﺧﺘﺒﺎرات اﻟﺪم*(

•   اﻟﻐﺜﯿﺎن )اﻟﺸﻌﻮر ﺑﺎﻟﻤﺮض(

•   اﻟﻀﻌﻒ واﻟﺘﻌﺐ*

•   آﻻم اﻟﻤﻔﺎﺻﻞ واﻟﻌﻀﻼت

•   اﻟﮭﺒﺎت اﻟﺴﺎﺧﻨﺔ

•   اﻟﻄﻔﺢ اﻟﺠﻠﺪي

•   ﺗﻔﺎﻋﻼت اﻟﺤﺴﺎﺳﯿﺔ )ﻓﺮط اﻟﺤﺴﺎﺳﯿﺔ(، ﺑﻤﺎ ﻓﻲ ذﻟﻚ ﺗﻮرم اﻟﻮﺟﮫ واﻟﺸﻔﺘﯿﻦ واﻟﻠﺴﺎن و/أو اﻟﺤﻠﻖ

 

ﺟﻤﯿﻊ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻷﺧﺮى:

اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺸﺎﺋﻌﺔ، قد تؤثر على  1 من كل 10 أشخاص:

•   اﻟﺼﺪاع

•   اﻟﻘﻲء أو اﻹﺳﮭﺎل أو ﻓﻘﺪان اﻟﺸﮭﯿﺔ*

•   اﻟﺘﮭﺎﺑﺎت اﻟﻤﺴﺎﻟﻚ اﻟﺒﻮﻟﯿﺔ

•   أﻟﻢ ﻓﻲ اﻟﻈﮭﺮ*

•   زﯾﺎدة اﻟﺒﯿﻠﯿﺮوﺑﯿﻦ )اﻟﺼﺒﺎغ اﻟﺼﻔﺮاوي اﻟﺬي ﯾﻨﺘﺠﮫ اﻟﻜﺒﺪ(

•   زﯾﺎدة ﺧﻄﺮ اﻟﺠﻠﻄﺎت اﻟﺪﻣﻮﯾﺔ *

•   اﻧﺨﻔﺎض ﻣﺴﺘﻮﯾﺎت اﻟﺼﻔﺎﺋﺢ اﻟﺪﻣﻮﯾﺔ )ﻧﻘﺺ اﻟﺼﻔﯿﺤﺎت اﻟﺪﻣﻮﯾﺔ(

•   ﻧﺰﯾﻒ ﻣﮭﺒﻠﻲ

•   أﻟﻢ أﺳﻔﻞ اﻟﻈﮭﺮ ﯾﻤﺘﺪ إﻟﻰ اﻟﺴﺎق ﻋﻠﻰ ﺟﺎﻧﺐ واﺣﺪ )ﻋﺮق اﻟﻨﺴﺎ(

• ﺿﻌﻒ ﻣﻔﺎﺟﺊ، أو ﺗﻨﻤﯿﻞ، أو وﺧﺰ، أو ﻓﻘﺪان اﻟﺤﺮﻛﺔ ﻓﻲ اﻟﺴﺎق، ﺧﺎﺻﺔ ﻋﻠﻰ ﺟﺎﻧﺐ واﺣﺪ ﻓﻘﻂ ﻣﻦ اﻟﺠﺴﻢ، أو ﻣﺸﺎﻛﻞ ﻣﻔﺎﺟﺌﺔ ﻓﻲاﻟﻤﺸﻲ أو اﻟﺘﻮازن )اﻻﻋﺘﻼل اﻟﻌﺼﺒﻲ اﻟﻤﺤﯿﻄﻲ(

اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻐﯿﺮ ﺷﺎﺋﻌﺔ، قد تصيب حتى 1 من كل 100 شخص:

   إﻓﺮازات ﻣﮭﺒﻠﯿﺔ ﺳﻤﯿﻜﺔ ﺑﯿﻀﺎء اﻟﻠﻮن وداء اﻟﻤﺒﯿﻀﺎت (ﻋﺪوى)

•   ﻛﺪﻣﺎت وﻧﺰﯾﻒ ﻓﻲ ﻣﻜﺎن اﻟﺤﻘﻦ

•   زﯾﺎدة ﻓﻲ ﺟﺎﻣﺎ ﺟﻲ ﺗﻲ، وھﻮ إﻧﺰﯾﻢ اﻟﻜﺒﺪ اﻟﺬي ﯾﻈﮭﺮ ﻓﻲ ﻓﺤﺺ اﻟﺪم

•   اﻟﺘﮭﺎب اﻟﻜﺒﺪ

•   اﻟﺘﻠﯿﻒ اﻟﻜﺒﺪى

•   اﻟﺨﺪر واﻟﻮﺧﺰ واﻷﻟﻢ

•   ردود اﻟﻔﻌﻞ اﻟﺘﺤﺴﺴﯿﺔ

ﺗﺸﻤﻞ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﻲ ﻻ ﯾﻤﻜﻦ ﺗﻘﯿﯿﻢ دور أﻣﺒﯿﻔﻮل اﻟﺪﻗﯿﻖ ﻓﯿﮭﺎ ﺑﺴﺒﺐ اﻟﻤﺮض اﻷﺳﺎﺳﻲ.

اﻹﺑﻼغ ﻋﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ

إذا أﺻﺒﺢ أي ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ ﺧﻄﯿ ًﺮا، أو إذا ﻻﺣﻈﺖ أي آﺛﺎر ﺟﺎﻧﺒﯿﺔ ﻏﯿﺮ ﻣﺪرﺟﺔ ﻓﻲ ھﺬه اﻟﻨﺸﺮة،

ﻓﯿﺮﺟﻰ إﺧﺒﺎر طﺒﯿﺒﻚ أو ﻣﻘﺪم اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ أو اﻟﺼﯿﺪﻟﻲ.

ﯾﺤﻔﻆ ھﺬا اﻟﺪواء ﺑﻌﯿﺪًا ﻋﻦ أﻧﻈﺎر وﻣﺘﻨﺎول اﻷطﻔﺎل.

 

ﻻ ﺗﺴﺘﺨﺪم ھﺬا اﻟﺪواء ﺑﻌﺪ ﺗﺎرﯾﺦ اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ اﻟﻤﺬﻛﻮر ﻋﻠﻰ اﻟﻌﺒﻮة اﻟﻜﺮﺗﻮﻧﯿﺔ أو ﻣﻠﺼﻘﺎت اﻟﺤﻘﻨﺔ

ﺑﻌﺪ ﻛﻠﻤﺔ ﺻﺎﻟﺢ ﺣﺘﻰ EXP.وﯾﺸﯿﺮ ﺗﺎرﯾﺦ اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ إﻟﻰ اﻟﯿﻮم اﻷﺧﯿﺮ ﻣﻦ ذﻟﻚ اﻟﺸﮭﺮ.

 

 

25درﺟﺔ ﻣﺌﻮﯾﺔ .ﻗﻢ ﺑﺘﺨﺰﯾﻦ اﻟﻤﺤﻘﻨﺔ اﻟﻤﻌﺒﺄة ﻣﺴﺒﻘًﺎ ﻓﻲ اﻟﻌﺒﻮة اﻷﺻﻠﯿﺔ

 

ﯾﺤﻔﻆ ﻓﻲ درﺟﺔ ﺣﺮارة أﻗﻞ ﻣﻦ

ﻟﺤﻤﺎﯾﺘﮭﺎ ﻣﻦ اﻟﻀﻮء.

 

ﺳﯿﻜﻮن أﺧﺼﺎﺋﻲ اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ اﻟﺨﺎص ﺑﻚ ﻣﺴﺆوﻻً ﻋﻦ ﺗﺨﺰﯾﻦ أﻣﺒﯿﻔﻮل واﺳﺘﺨﺪاﻣﮫ واﻟﺘﺨﻠﺺ ﻣﻨﮫ

ﺑﺸﻜﻞ ﺻﺤﯿﺢ.

ﻗﺪ ﯾﺸﻜﻞ ھﺬا اﻟﺪواء ﺧﻄﺮاً ﻋﻠﻰ اﻟﺒﯿﺌﺔ اﻟﻤﺎﺋﯿﺔ.

 

ﻻ ﺗﺘﺨﻠﺺ ﻣﻦ أي أدوﯾﺔ ﻋﻦ طﺮﯾﻖ ﻣﯿﺎه اﻟﺼﺮف اﻟﺼﺤﻲ أو اﻟﻨﻔﺎﯾﺎت اﻟﻤﻨﺰﻟﯿﺔ .اﺳﺄل اﻟﺼﯿﺪﻟﻲ ﻋﻦ

ﻛﯿﻔﯿﺔ اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ اﻟﺘﻲ ﻟﻢ ﺗﻌﺪ ﺗﺴﺘﺨﺪﻣﮭﺎ .ھﺬه اﻟﺘﺪاﺑﯿﺮ ﺳﻮف ﺗﺴﺎﻋﺪ ﻓﻲ ﺣﻤﺎﯾﺔ اﻟﺒﯿﺌﺔ.

 

اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ھﻲ ﻓﻮﻟﻔﯿﺴﺘﺮاﻧﺖ ﺗﺤﺘﻮي ﻛﻞ ﺣﻘﻨﺔ (ﻣﻞ5 ) ﻣﻌﺒﺄة ﻣﺴﺒﻘﺎً ﻋﻠﻰ 250 ملغ ﻣﻦ ﻣﺎدة ﻓﻮﻟﻔﯿﺴﺘﺮاﻧﺖ

ﯾﺤﺘﻮي ﻛﻞ ﻣﻞ ﻋﻠﻰ 50ﻣﻠﻎ ﻣﻦ ﻣﺎدة ﻓﻮﻟﻔﯿﺴﺘﺮاﻧﺖ

- اﻟﻤﻜﻮﻧﺎت اﻷﺧﺮى (اﻟﺴﻮاﻏﺎت)  ھﻲ اﻹﯾﺜﺎﻧﻮل (96%)، ﻛﺤﻮل اﻟﺒﻨﺰﯾﻞ، ﺑﻨﺰوات اﻟﺒﻨﺰﯾﻞ، زﯾﺖ اﻟﺨﺮوع اﻟﺒﻜﺮ.

- ﺗﺤﺘﻮي ﻛﻞ ﺣﻘﻨﺔ ﻣﻌﺒﺄة ﻣﺴﺒﻘﺎً ﻋﻠﻰ 10% ﻣﻦ اﻹﯾﺜﺎﻧﻮل اﻟﻜﺤﻮل،  أي ﻣﺎ ﯾﺼﻞ إﻟﻰ 500ﻣﻠﻎ من اﻹﯾﺜﺎﻧﻮل 

- ﻛﻞ ﻣﺤﻘﻨﺔ ﺟﺎھﺰة ﻟﻺﺳﺘﻌﻤﺎل ﺗﺤﺘﻮي ﻋﻠﻰ 500ﻣﻠﻎ ﻣﻦ ﻛﺤﻮل اﻟﺒﻨﺰﯾﻞ أي ﻣﺎ ﯾﻌﺎدل 100ﻣﻠﻎ/مل

ﻛﻞ ﻣﺤﻘﻨﺔ ﺟﺎھﺰة ﻟﻺﺳﺘﻌﻤﺎل ﺗﺤﺘﻮي ﻋﻠﻰ 750ﻣﻠﻎ ﻣﻦ ﺑﻨﺰﯾﻞ ﺑﻨﺰوات أي ﻣﺎ ﯾﻌﺎدل 150ﻣﻠﻎ/مل

أﻣﺒﯿﻔﻮل ھﻮ ﻣﺤﻠﻮل ﻟﺰج ﻋﺪﯾﻢ اﻟﻠﻮن ﻣﺎﺋﻞ إﻟﻰ أﺻﻔﺮ، ﻋﻤﻠﯿﺎً ھﻮ ﺧﺎﻟﻲ ﻣﻦ اﻟﺠﺰﯾﺌﺎت، ﻓﻲ ﻣﺤﻘﻨﺔ زﺟﺎﺟﯿﺔ ﻣﻦ اﻟﻨﻮع اﻷولﻣﻌﺒﺄة ﻣﺴﺒﻘًﺎ ﻣﺰودة ﺑﺴﺪادة ﻣﻄﺎطﯿﺔ ﻣﻦ اﻟﺒﺮوﻣﻮﺗﯿﻞ، وﻗﻀﯿﺐ ﻣﻜﺒﺲ وﻣﺴﻨﺪ ﺧﻠﻔﻲ، ﻣﺰودة ﺑﺈﻏﻼق ﯾﻈﮭﺮ إذا ﻣﺎ ﺣﺪث ﺑﮫ ﺗﻼﻋﺐ، ﺗﺤﺘﻮي ﻋﻠﻰ ﻣﺤﻠﻮل 5ﻣﻞ ﻟﻠﺤﻘﻨﺔ .ﯾﺠﺐ إﻋﻄﺎء ﻣﺤﻘﻨﺘﯿﻦ ﻟﺘﻠﻘﻲ اﻟﺠﺮﻋﺔ اﻟﺸﮭﺮﯾﺔ اﻟﻤﻮﺻﻰ ﺑﮭﺎ اﻟﺒﺎﻟﻐﺔ 500ﻣﻠﻎ.

ﯾﺤﺘﻮي أﻣﺒﯿﻔﻮل ﻋﻠﻰ ﻋﺒﻮﺗﯿﻦ ﺗﻘﺪﯾﻤﯿﺘﯿﻦ، إﻣﺎ ﻋﺒﻮة ﺗﺤﺘﻮي ﻋﻠﻰ ﺣﻘﻨﺔ زﺟﺎﺟﯿﺔ ﻣﻌﺒﺄة ﻣﺴﺒﻘًﺎ أو ﻋﺒﻮة ﺗﺤﺘﻮي ﻋﻠﻰ ﺣﻘﻨﺘﯿﻦ زﺟﺎﺟﯿﺘﯿﻦ ﻣﻌﺒﺄﺗﯿﻦ ﻣﺴﺒﻘًﺎ يتم ايضا توفير ابر امان مقاس 1½ × 21Gﺑﻮﺻﺔ (™BD SafetyGlide) للتوصيل ﺑﻜﻞ أﺳﻄﻮاﻧﺔ.

اﻟﺤﺰﻣﺔ:

2  × 2 ﺣﻘﻨﺔ ﻣﻌﺒﺄة ﻣﺴﺒﻘًﺎ (5ﻣﻞ ﻟﻜﻞ ﻣﻨﮭﻤﺎ)

2 × 3 ﺣﻘﻨﺔ ﻣﻌﺒﺄة ﻣﺴﺒﻘﺎً( 5ﻣﻞ ﻟﻜﻞ ﻣﻨﮭﻤﺎ)

ﻗﺪ ﻻ ﯾﺘﻢ ﺗﺴﻮﯾﻖ ﺟﻤﯿﻊ أﺣﺠﺎم اﻟﻌﺒﻮات.

ﺻﺎﺣﺐ ﺗﺮﺧﯿﺺ اﻟﺘﺴﻮﯾﻖ

EVER Valinject GmbH

أوﺑﺮﺑﻮرﺟﺎو 3 4866أوﻧﺘﺮاخ آم أﺗﯿﺮﺳﻲ

اﻟﻨﻤﺴﺎ

 

اﻟﺸﺮﻛﺔ اﻟﺼﺎﻧﻌﺔ ﺷﺮﻛﺔ إﯾﻔﺮ ﻓﺎرﻣﺎ ﺟﯿﻨﺎ اﻟﻤﺤﺪودة أوﺗﻮ-ﺷﻮت-ﺷﺘﺮاﺳﮫ 15

07745ﺟﯿﻨﺎ

أﻟﻤﺎﻧﯿﺎ

يوليو 2020
 لم يتم إدخال بيانات نشرة الممارس الصحي لهذا الدواء حتى الآن

صورة المنتج على الرف

الصورة الاساسية